Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine pilot phase I study in first relapsed infant MLL-rearranged B-cell precursor ALL
jRCTs031180063Phase 1Completed
- Sponsor
- National Center for Child Health and Development
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine in acute lymphoblastic leukemia (ALL) and B-lymphoblastic leukemia/lymphoma with KMT2A rearrangement, sponsored by National Center for Child Health and Development. Primary endpoint: Occurrence rate of dose-limiting toxicity. Started Jun 2020; status: completed.
02
Drugs
azacitidine
03
Conditions
acute lymphoblastic leukemia (ALL)B-lymphoblastic leukemia/lymphoma with KMT2A rearrangement
Beyond the preview
Go deeper on jRCTs031180063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180063.